Compare KRP & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KRP | KARD |
|---|---|---|
| Founded | 2013 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2017 | 2026 |
| Metric | KRP | KARD |
|---|---|---|
| Price | $15.42 | $14.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $19.20 | ★ $41.13 |
| AVG Volume (30 Days) | ★ 839.8K | 513.7K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 10.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $333,830,000.00 | N/A |
| Revenue This Year | $23.40 | N/A |
| Revenue Next Year | $2.71 | $50.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.93 | N/A |
| 52 Week Low | $11.31 | $12.23 |
| 52 Week High | $17.12 | $27.00 |
| Indicator | KRP | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 48.64 |
| Support Level | $14.54 | $13.75 |
| Resistance Level | $15.56 | $15.93 |
| Average True Range (ATR) | 0.36 | 1.21 |
| MACD | -0.19 | 0.26 |
| Stochastic Oscillator | 25.67 | 47.78 |
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.